Skip to main content
Top
Published in: Journal of Translational Medicine 1/2011

Open Access 01-12-2011 | Editorial

Personalized medicine: a patient - centered paradigm

Authors: Lotfi Chouchane, Ravinder Mamtani, Ashraf Dallol, Javaid I Sheikh

Published in: Journal of Translational Medicine | Issue 1/2011

Login to get access

Excerpt

An editorial about personalized medicine should perhaps start with a definition. Although several versions of such definition exist, we pay homage here to the oldest definition reported in modern medical literature. Sir William Osler (1849-1919) recognized that "variability is the law of life, and as no two faces are the same, so no two bodies are alike, and no two individuals react alike and behave alike under the abnormal conditions we know as disease". Modern day medicine recognized this fact and implemented its ethos since inception of its practice separating it from a general "one-size-fits-all" approach. A medical doctor would ask the patient about his/her suffering and prescribe a treatment suited to the patient's condition. Individualized evaluation and treatments, which include history taking, focused examination and specific laboratory and medical tests have now become routine in day-to-day medical practice. Personalized medicine, takes into account the needs of individual patients, and provides custom-tailored therapeutic approaches. …
Literature
1.
go back to reference Hong K-W, Oh B: Overview of personalized medicine in the disease genomic era. BMB Reports. 2010, 43: 643-8. 10.5483/BMBRep.2010.43.10.643.CrossRefPubMed Hong K-W, Oh B: Overview of personalized medicine in the disease genomic era. BMB Reports. 2010, 43: 643-8. 10.5483/BMBRep.2010.43.10.643.CrossRefPubMed
2.
go back to reference Kamali F, Wynee H: Pharmacogenetics of warfarin. Annu Rev Med. 2010, 61: 63-75. 10.1146/annurev.med.070808.170037.CrossRefPubMed Kamali F, Wynee H: Pharmacogenetics of warfarin. Annu Rev Med. 2010, 61: 63-75. 10.1146/annurev.med.070808.170037.CrossRefPubMed
3.
go back to reference Voora D, McLeod HL, Eby C, Gage BF: The pharmacogenetics of coumarin therapy. Pharmacogenomics. 2005, 6: 503-513. 10.2217/14622416.6.5.503.CrossRefPubMed Voora D, McLeod HL, Eby C, Gage BF: The pharmacogenetics of coumarin therapy. Pharmacogenomics. 2005, 6: 503-513. 10.2217/14622416.6.5.503.CrossRefPubMed
4.
go back to reference Rettie AE, Tai G: The pharmacogenomics of warfarin: closing in on personalized medicine. Mol Interv. 2006, 6: 223-227. 10.1124/mi.6.4.8.CrossRefPubMed Rettie AE, Tai G: The pharmacogenomics of warfarin: closing in on personalized medicine. Mol Interv. 2006, 6: 223-227. 10.1124/mi.6.4.8.CrossRefPubMed
5.
go back to reference Flockhart DA, O'Kane D, Williams MS: Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med. 2008, 10: 139-150. 10.1097/GIM.0b013e318163c35f.CrossRefPubMed Flockhart DA, O'Kane D, Williams MS: Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med. 2008, 10: 139-150. 10.1097/GIM.0b013e318163c35f.CrossRefPubMed
6.
go back to reference Goldenberg MM: Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther. 1999, 21: 309-318. 10.1016/S0149-2918(00)88288-0.CrossRefPubMed Goldenberg MM: Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther. 1999, 21: 309-318. 10.1016/S0149-2918(00)88288-0.CrossRefPubMed
8.
go back to reference Di Blasi Z, Harkness E, Ernst E, Georgioud A, Kleijnen J: Influence of context effects on health outcomes: a systematic review. The Lancet. 2001, 37: 757-762.CrossRef Di Blasi Z, Harkness E, Ernst E, Georgioud A, Kleijnen J: Influence of context effects on health outcomes: a systematic review. The Lancet. 2001, 37: 757-762.CrossRef
9.
go back to reference Everson SA, Kaplan GA, Goldberg DE, Salonen R, Salonen JT: Hopelessness and 4-year progression of carotid atherosclerosis. The Kuopio Ischemic Heart Disease Risk Factor Study. Arterioscler Thromb Vasc Biol. 1997, 17: 1490-495. 10.1161/01.ATV.17.8.1490.CrossRefPubMed Everson SA, Kaplan GA, Goldberg DE, Salonen R, Salonen JT: Hopelessness and 4-year progression of carotid atherosclerosis. The Kuopio Ischemic Heart Disease Risk Factor Study. Arterioscler Thromb Vasc Biol. 1997, 17: 1490-495. 10.1161/01.ATV.17.8.1490.CrossRefPubMed
10.
go back to reference Armstrong D: 'Public health spaces and the fabrication of identity':. Sociology. 1993, 27: 393-410.CrossRef Armstrong D: 'Public health spaces and the fabrication of identity':. Sociology. 1993, 27: 393-410.CrossRef
11.
go back to reference Furmark T, Appel L, Henningsson S: A link between serotinin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety. The Journal of Neuroscience. 2008, 28: 13066-13074. 10.1523/JNEUROSCI.2534-08.2008.CrossRefPubMed Furmark T, Appel L, Henningsson S: A link between serotinin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety. The Journal of Neuroscience. 2008, 28: 13066-13074. 10.1523/JNEUROSCI.2534-08.2008.CrossRefPubMed
Metadata
Title
Personalized medicine: a patient - centered paradigm
Authors
Lotfi Chouchane
Ravinder Mamtani
Ashraf Dallol
Javaid I Sheikh
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2011
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-9-206

Other articles of this Issue 1/2011

Journal of Translational Medicine 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.